Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Calcifediol Treatment and COVID-19-Related Outcomes
Posted: 22 Jan 2021
More...Abstract
Dear Preprints with the Lancet Readers,
We removed this preprint due to concerns about the description of the research in this paper. This led us to initiate an investigation into this study.
Following the conclusion of an investigation into this study by the National Centre of Biomedical Research on Frailty and Healthy Aging (CIBERFES), Spain, the report concluded that: 1) In the elaboration of the manuscript and the correspondence of the authors with the Journal, there was a series of mistakes made by the authors in the qualification of the study and its description; and 2) At all times good practices for clinical research were carefully followed and in no case was the health of the patients put at any risk.
The comments that have been posted on this preprint will remain available on this page. Please note that this comment thread is now closed to further posts.
Suggested Citation: Suggested Citation